問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Cardiovascular Diseases

Division of Cardiovascular Diseases

Kaohsiung Municipal Ta-Tung Hospital (在職)

更新時間：2023-09-19

林宗憲Lin, Tsung-Hsien
  • Principal Investigator
  • Clinical Trial Experience (year) -23 years -4 個月

Recruiting Trial

52Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林宗憲

List

114Cases

2007-09-01 - 2008-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2010-10-01 - 2016-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2010-04-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Study ended7Sites

2013-01-10 - 2015-12-31

Phase III

A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C

  • Condition/Disease

    Hyperlipidemia

  • Test Drug

    MK859/Placebo

Participate Sites
9Sites

Terminated9Sites

2010-08-30 - 2012-11-30

Phase III

A Phase III, Prospective, Randomized, Double-Blind, PlaceboControlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients with Atrial Fibrillation

  • Condition/Disease

    Atrial Fibrillation

  • Test Drug

    MK-6621

Participate Sites
16Sites

Terminated16Sites

2014-01-01 - 2016-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2014-01-31 - 2018-04-30

Phase IV

高血管風險之第2型糖尿病病患使用LINAgliptin 5 mg每天1次的一項多中心、國際性、隨機分配、平行分組、雙盲、安慰劑對照、心血管安全性及腎臟微血管結果試驗。

  • Condition/Disease

    DM

  • Test Drug

    Trajenta® (BI 1356)

Participate Sites
4Sites

Terminated4Sites

2014-12-01 - 2017-07-21

Phase III

A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients with Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) Trial

  • Condition/Disease

    Cardiovascular Disease

  • Test Drug

    AMG 145

Participate Sites
8Sites

Terminated8Sites

2009-02-15 - 2012-09-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Terminated16Sites

2012-12-01 - 2016-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Study ended8Sites

1 8 9 10 11 12
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB